Wednesday, July 8, 2026

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS is a pharma organization headquartered in Morrisville, USA. It trades on NYSE under ticker TGTX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia, Relapsing Multiple Sclerosis, Hodgkin

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Clinical program

Ublituximab

Unknown · small molecule · Multiple Sclerosis (MS) - Relapsing-remitting

Ublituximab for Multiple Sclerosis (MS) - Relapsing-remitting is a Unknown program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All TG THERAPEUTICS, INC. projects Unknown small molecule active

Internal code HP-00113916

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TG THERAPEUTICS, INC.
Phase
Unknown
Modality
small_molecule
Indication
Multiple Sclerosis (MS) - Relapsing-remitting
Status
active
Trials
1